Urolithin A

Urolithin A is a 6.5–7.0/10 fit for people considering mitochondrial, muscle growth, endurance cardio, anti inflammatory, with the strongest case in the populations already represented by the evidence rather than broad wellness use. Hodzic 2024 and Watts 2025 give the report its main anchors, while the score stays Worth trying because benefits are context-dependent and the evidence still leaves responder, dose, and long-term questions open. Urolithin A makes the most sense when the target is concrete, such as a lab marker, symptom pattern, training limitation, or recovery bottleneck. It makes less sense as a background habit taken on faith. In practice, treat Urolithin A as a tracked experiment: define the outcome first, watch for tradeoffs, and let the response decide whether it earns a place.

✅ Best for: Older adults, sedentary adults, post-illness rebuild phases, and people who suspect poor mitochondrial resilience but want a low-effort intervention. Urolithin A is also more compelling if you are a likely non-producer from ellagitannin foods, because direct supplementation bypasses the gut-bacteria bottleneck described by Selma 2014. Use Mitopure if you want the closest match to the human trial literature. Run it for 12-16 weeks, track something objective, and treat biomarker improvements as more likely than a dramatic felt energy change.

❌ Avoid if: You are price-sensitive, already highly fit, pregnant, nursing, buying unverified generics, or expecting a fast subjective nootropic or energy effect. Avoid using urolithin A as a cancer, cognition, cardiovascular, hormone, or disease-treatment intervention. Francisco 2026 is preclinical colorectal-cancer synthesis, not human treatment evidence. Athletes should also remember that urolithin A was not found as a named WADA-banned substance in the audit, but supplement contamination and label risk still apply.